 It's seem that the HAS has a some influence in North Africa region, especially for the drugs without clinical add value (ASMR 5).  Algeria, Tunisia and Morocco appear to be a market linked: with a convergence in the reimbursement decisions , and a common access of similar medicines :
Which have a same "degree of innovation" as well as a same therapeutic areas.  However the prices were not be considered in the study, therefore we cannot conclude on the effect of high prices on the making decision  Similarly, the delays of access in the Maghreb were not been take in account  It could be interesting to discuss in deep about these issues in a future study. 
OBJECTIVES METHODS
We identified a drug sample assessed by the HAS during a period from January 2012 to December 2014: All of these drugs obtained a positive recommendation ( ASMR 1 to ASMR 5) in their prior inscription.
 We determined 182 medicines from HAS website :  The three countries promote widely the access to drugs without clinical add value ASMR 5  Tunisia allows the access to more innovative drugs followed by Algeria And Morocco.
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 The availability of drugs according the therapeutic areas
 Regarding the sample, the most reimbursed are the Analgesic drugs followed by Cardiology drugs  However, in terms of quantity : Cancer drugs are the most available in North Africa. 
